Cargando…
Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
BACKGROUND: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were t...
Autores principales: | Laloi, Louise, Billotey, Natacha Chaumard, Dumas, Pierre‐Yves, Paul, Franciane, Villate, Alban, Simand, Célestine, Fornecker, Luc, Puisset, Florent, Bertoli, Sarah, Simonet, Marion Boissard, Laribi, Kamel, Houyou, Dyhia, Santagostino, Alberto, Michel, Claire, Guepin, Gabrielle Roth, Guerineau, Elodie, Tabrizi, Reza, Hunault, Mathilde, Giltat, Aurélien, Kaphan, Eléonore, Bulabois, Claude, Cartet, Elodie, Rocher, Clément, Lachenal, Florence, Morisset, Stéphane, Récher, Christian, Pigneux, Arnaud, Belhabri, Amine, Michallet, Mauricette, Michallet, Anne‐Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067034/ https://www.ncbi.nlm.nih.gov/pubmed/36482507 http://dx.doi.org/10.1002/cam4.5459 |
Ejemplares similares
-
Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies
por: Pan, Hua, et al.
Publicado: (2016) -
Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014) -
Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020) -
Incidence of Hospital-Acquired Pneumonia, Bacteraemia and Urinary Tract Infections in Patients with Haematological Malignancies, 2004–2010: A Surveillance-Based Study
por: Huoi, Catherine, et al.
Publicado: (2013) -
Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)